Details for New Drug Application (NDA): 215203
✉ Email this page to a colleague
NDA 215203 describes LOTEPREDNOL ETABONATE, which is a drug marketed by Hikma, Sentiss, Sun Pharm, Lupin Ltd, and Padagis Us, and is included in nine NDAs. It is available from three suppliers. Additional details are available on the LOTEPREDNOL ETABONATE profile page.
The generic ingredient in LOTEPREDNOL ETABONATE is loteprednol etabonate. There are ten drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the loteprednol etabonate profile page.
The generic ingredient in LOTEPREDNOL ETABONATE is loteprednol etabonate. There are ten drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the loteprednol etabonate profile page.
Summary for 215203
| Tradename: | LOTEPREDNOL ETABONATE |
| Applicant: | Padagis Us |
| Ingredient: | loteprednol etabonate |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 215203
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SUSPENSION/DROPS;OPHTHALMIC | Strength | 0.2% | ||||
| Approval Date: | Jul 10, 2024 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
